All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Guillermo Sanz, Hospital Universitari i Politècnic La Fe, Valencia, ES. We asked, Should omidubicel become standard of care (SOC) for umbilical cord blood transplantation?
Should omidubicel become SOC for umbilical cord blood transplantation?
In this video, Sanz discusses the outcomes of a phase III randomized study focusing on omidubicel, an ex vivo expanded cord blood product. The trial compared the efficacy of omidubicel to standard umbilical cord blood transplantation in patients with hematologic malignancies. Results suggest neutrophil engraftment was faster with omidubicel and the clinical benefits were greater.
Molecular profiling at diagnosis for risk stratification of patients with AML undergoing allogeneic transplant in first remission
Moses Murdock from the Dana Farber Cancer Institute, Philadelphia, US, and colleagues undertook a retrospective...
How can CMV infection increase the risk of chronic GvHD?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Katrine Kielsen, Rigshospitalet, Copenhagen, DK. We asked, How can CMV...
Subscribe to get the best content related to GvHD delivered to your inbox